New combo therapy aims to improve survival in hard-to-treat nose and throat cancer

NCT ID NCT07459296

Recruiting now Disease control Sponsor: First Affiliated Hospital of Guangxi Medical University Source: ClinicalTrials.gov ↗

First seen Mar 16, 2026 · Last updated Apr 24, 2026 · Updated 6 times

Summary

This phase 3 trial tests whether adding the drug Becotatug vedotin and immunotherapy (sintilimab) to standard chemoradiotherapy can improve outcomes for people with high-risk nasopharyngeal carcinoma. About 266 adults with advanced, non-spreading cancer will be randomly assigned to the new combination or standard treatment. The study tracks how long participants live without the cancer returning or spreading, as well as side effects and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The First Affiliated Hospital of Guangxi Medical University
RECRUITING

Nanning, Guangxi, 530021, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NASOPHARYNGEAL CARCINOMA (NPC)